A Agilent Technologies Inc.

Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon

(NYSE: A) today announced the launch of the , a sensitive flow cytometer with five lasers and up to 30 fluorescence channels. The NovoCyte Penteon provides excellent sensitivity, resolution, speed, and flexibility. It has a large dynamic range of 7.2 log, along with fully automated compensation features, enabling users to pick up both dim and bright signals in the same run.

“The NovoCyte Penteon provides expanded capabilities of UV laser excitation that accommodate multicolor flow cytometry assays which are becoming increasingly sophisticated,” stated Xiaobo Wang, Ph.D., who joined Agilent from ACEA, as general manager of the Flow Cytometry and Real-Time Cell Analysis Business. “The NovoCyte Penteon is continuing the NovoCyte legacy of great cytometry performance matched with intuitiveness and simplicity of user experience.”

“NovoCyte Penteon is expanding Agilent’s offering of advanced flow cytometer instrumentation,” stated Todd Christian, vice president, and general manager of Agilent's Cell Analysis Division. “Agilent is committed to continuing our innovation for trusted cell analysis solutions, to support scientists of the world in their endeavor of scientific and therapeutic discovery for advancing the human condition.”

The resolution easily discerns particles in the range of 100 nanometers, and the precision fluidics are considered to be among the best on the market. Coupled with the power of the highly intuitive NovoExpress software package, the system can be fully automated and is easy to use, providing an exceptional user experience in data acquisition, analysis, and reporting.

The product line is an innovative breakthrough in flow cytometry. It capitalizes on the global success of the Agilent line of flow cytometers, including the NovoCyte, the NovoCyte Quanteon, and the NovoCyte Advanteon.

Flow cytometry technology is integral to basic research, drug discovery, and clinical diagnostics. Currently, a major trend in flow cytometry is to measure more parameters simultaneously, especially useful in monitoring for certain blood disorders and in the field of immuno-oncology.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
17/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch